Kiora Pharmaceuticals (NASDAQ:KPRX) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Kiora Pharmaceuticals (NASDAQ:KPRX) in a report published on Tuesday,Benzinga reports. HC Wainwright currently has a $10.00 price target on the stock. HC Wainwright also issued estimates for Kiora Pharmaceuticals’ Q4 2024 earnings at ($0.74) EPS, FY2024 earnings at $1.28 EPS, Q1 2025 earnings at $0.67 EPS and FY2025 earnings at ($2.76) EPS.

Kiora Pharmaceuticals Stock Performance

KPRX stock traded down $0.13 during midday trading on Tuesday, hitting $3.27. The company’s stock had a trading volume of 17,138 shares, compared to its average volume of 73,577. Kiora Pharmaceuticals has a 52-week low of $3.00 and a 52-week high of $8.98. The firm has a 50-day simple moving average of $3.52 and a 200-day simple moving average of $4.28.

Kiora Pharmaceuticals (NASDAQ:KPRX) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.09. On average, research analysts predict that Kiora Pharmaceuticals will post 0.89 EPS for the current fiscal year.

Institutional Investors Weigh In On Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC acquired a new stake in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals makes up 0.8% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 16th biggest position. Stonepine Capital Management LLC owned approximately 6.86% of Kiora Pharmaceuticals at the end of the most recent reporting period. 76.97% of the stock is currently owned by institutional investors and hedge funds.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.